Bio-Rad Laboratories, Inc. BIO posted fourth-quarter 2025 adjusted earnings per share (EPS) of $2.51, which missed the Zacks Consensus Estimate by 2.3%. The bottom line decreased 13.4% from the ...

IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for approval regardless. The company said that the study "narrowly missed" the ...

At Week 24, patients receiving seralutinib showed a median change of +28.2 meters in the Six-Minute Walk Distance (6MWD) from baseline, compared to a +13.5 meters change for the placebo group. The ...

The San Diego-based biotech firm Gossamer Bio announced today that it still intends to seek a regulatory path forward with the FDA for its lead drug, seralutinib, despite the treatment narrowly ...

Investing.com - Leerink Partners downgraded Gossamer Bio Inc. (NASDAQ:GOSS) to Market Perform from Outperform on Tuesday and lowered its price target to $1.00 from $6.00. The stock plunged 80% in the ...

The drug was generally well tolerated, with treatment-emergent adverse events reported in 86.5% of patients receiving seralutinib versus 80.5% on placebo. Cough was the most frequently reported ...

Pooja Vastrakar, the Royal Challengers Bengaluru pace bowling all-rounder, is ruled out of action for two weeks due to a hamstring injury, RCB head coach Malolan Rangarajan confirmed on Friday ...